Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation. (2017). Farmeconomia. Health Economics and Therapeutic Pathways, 18(1). https://doi.org/10.7175/fe.v18i1.1327